Download Files:

NF279

$220$490

Products Details

Product Description

– NF279 is a potent selective and reversible P2X1 receptor antagonist, with an IC50 of 19 nM. NF279 displays good selectivity over P2X2, P2X3 (IC50=1.62 μM), P2X4 (IC50>300 μM). NF279 is a dual HIV-1 coreceptor inhibitor that interferes with the functional engagement of CCR5 and CXCR4 by Env[1][2].

Web ID

– HY-D0976

Storage Temperature

– -20°C (Powder, sealed storage, away from moisture)

Shipping

– Blue Ice

Molecular Formula

– C49H30N6Na6O23S6

References

– [1]Rettinger J, Schmalzing G, Damer S, Müller G, Nickel P, Lambrecht G. The suramin analogue NF279 is a novel and potent antagonist selective for the P2X(1) receptor. Neuropharmacology. 2000;39(11):2044-2053.|[2]Giroud C, et al. P2X1 Receptor Antagonists Inhibit HIV-1 Fusion by Blocking Virus-Coreceptor Interactions. J Virol. 2015;89(18):9368-9382.

CAS Number

– 202983-32-2

Molecular Weight

– 1401.12

Compound Purity

– 98.0

SMILES

– O=C(NC1=CC=C(C=C1)C(NC2=CC=C(C=C2)C(NC3=CC=C(S(=O)(O[Na])=O)C4=CC(S(=O)(O[Na])=O)=CC(S(=O)(O[Na])=O)=C34)=O)=O)NC5=CC=C(C=C5)C(NC6=CC=C(C=C6)C(NC7=CC=C(S(=O)(O[Na])=O)C8=CC(S(=O)(O[Na])=O)=CC(S(=O)(O[Na])=O)=C78)=O)=O

Clinical Information

– No Development Reported

Research Area

– Infection

Solubility

– 10 mM in DMSO

Target

– HIV;P2X Receptor

Isoform

– HIV-1;P2X1 Receptor

Pathway

– Anti-infection;Membrane Transporter/Ion Channel

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.